drugset / Trial / NCT07400588
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
Phase 2
Active not recruiting
58 enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
Timeline
- Start
- 2025-12-01
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleniglipron | Small molecule | 240 mg | Oral |